Syamprasad NP - Search Results

1

AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma.

Syamprasad NP, Jain S, Rajdev B, Panda SR, Kumar GJ, Shaik KM, Shantanu PA, Challa VS, Jorvekar SB, Borkar RM, Vaidya JR, Tripathi DM, Naidu VGM. Syamprasad NP, et al. JHEP Rep. 2023 Nov 28;6(2):100974. doi: 10.1016/j.jhepr.2023.100974. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38283757 Free PMC article.

2

Apoptosis-driven synergistic anti-cancer efficacy of ethyl acetate extract of Memecylon sisparense Gamble leaves and doxorubicin in in-vitro and in-vivo models of triple-negative breast cancer.

Uppu JL, Challa VS, Syamprasad NP, Manepalli P, Naidu V, Syed A, Roshan S, Tazneem B, Almalki WH, Alharbi KS, Gupta G. Uppu JL, et al. Among authors: syamprasad np. Pathol Res Pract. 2024 Jan;253:155032. doi: 10.1016/j.prp.2023.155032. Epub 2023 Dec 18. Pathol Res Pract. 2024. PMID: 38176306

3

Molecular dissection of anti-colon cancer activity of NARI-29: special focus on H₂O₂ modulated NF-κB and death receptor signaling.

Np S, Rajdev B, Jain S, Gangasani JK, Vaidya JR, Naidu V. Np S, et al. Free Radic Res. 2023 Apr;57(4):308-324. doi: 10.1080/10715762.2023.2243029. Epub 2023 Aug 7. Free Radic Res. 2023. PMID: 37523668

4

AKR1B1 inhibition using NARI-29-an Epalrestat analogue-alleviates Doxorubicin-induced cardiotoxicity via modulating Calcium/CaMKII/MuRF-1 axis.

Syamprasad NP, Jain S, Rajdev B, Panda SR, Gangasani JK, Challa VS, Vaidya JR, Kundu GC, Naidu VGM. Syamprasad NP, et al. Chem Biol Interact. 2023 Aug 25;381:110566. doi: 10.1016/j.cbi.2023.110566. Epub 2023 May 29. Chem Biol Interact. 2023. PMID: 37257577

5

Pivotal role of AKR1B1 in pathogenesis of colitis associated colorectal carcinogenesis.

Syamprasad NP, Rajdev B, Jain S, Panda SR, Puppala ER, Chaudhari P, Vaidya JR, Kumar GJ, Naidu VGM. Syamprasad NP, et al. Int Immunopharmacol. 2023 Jun;119:110145. doi: 10.1016/j.intimp.2023.110145. Epub 2023 Apr 10. Int Immunopharmacol. 2023. PMID: 37044030

6

Aldose reductase and cancer metabolism: The master regulator in the limelight.

Syamprasad NP, Jain S, Rajdev B, Prasad N, Kallipalli R, Naidu VGM. Syamprasad NP, et al. Biochem Pharmacol. 2023 May;211:115528. doi: 10.1016/j.bcp.2023.115528. Epub 2023 Apr 1. Biochem Pharmacol. 2023. PMID: 37011733 Review.

7

Targeting TLR4/3 using chlorogenic acid ameliorates LPS+POLY I:C-induced acute respiratory distress syndrome via alleviating oxidative stress-mediated NLRP3/NF-κB axis.

Jain S, Saha P, Syamprasad NP, Panda SR, Rajdev B, Jannu AK, Sharma P, Naidu VGM. Jain S, et al. Among authors: syamprasad np. Clin Sci (Lond). 2023 May 31;137(10):785-805. doi: 10.1042/CS20220625. Clin Sci (Lond). 2023. PMID: 36951146

8

Mesua assamica (King&Prain) kosterm. Bark ethanolic extract attenuates chronic restraint stress aggravated DSS-induced ulcerative colitis in mice via inhibition of NF-κB/STAT3 and activation of HO-1/Nrf2/SIRT1 signaling pathways.

Puppala ER, Yalamarthi SS, Aochenlar SL, Prasad N, Syamprasad NP, Singh M, Nanjappan SK, Ravichandiran V, Tripathi DM, Gangasani JK, Naidu VGM. Puppala ER, et al. Among authors: syamprasad np. J Ethnopharmacol. 2023 Jan 30;301:115765. doi: 10.1016/j.jep.2022.115765. Epub 2022 Oct 1. J Ethnopharmacol. 2023. PMID: 36195303

9

Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF-κB and Keap1/Nrf2 signaling pathways: A comprehensive study onin-vitro and in-vivo experimental models.

Puppala ER, Jain S, Saha P, Rachamalla M, Np S, Yalamarthi SS, Abubakar M, Chaudhary A, Chamundeswari D, Usn M, Gangasani JK, Naidu VGM. Puppala ER, et al. Among authors: np s. Phytomedicine. 2022 Mar;97:153926. doi: 10.1016/j.phymed.2022.153926. Epub 2022 Jan 4. Phytomedicine. 2022. PMID: 35030388

10

Perillyl alcohol inhibits keratinocyte proliferation and attenuates imiquimod-induced psoriasis like skin-inflammation by modulating NF-κB and STAT3 signaling pathways.

Sudha Yalamarthi S, Puppala ER, Abubakar M, Saha P, Challa VS, Np S, Usn M, Gangasani JK, Naidu VGM. Sudha Yalamarthi S, et al. Among authors: np s. Int Immunopharmacol. 2022 Feb;103:108436. doi: 10.1016/j.intimp.2021.108436. Epub 2021 Dec 18. Int Immunopharmacol. 2022. PMID: 34929480

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11 results

Search Page